Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bipolar depression: specific treatments

W Z Potter1

  • 1Nervous System Disorders, Clinical Research, Lilly Research Laboratories, Indianapolis, Ind 46285, USA.

The Journal of Clinical Psychiatry
|December 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Schizophrenia research·2023
Same author

The Role of Metabolites of Antidepressants in the Treatment of Depression.

CNS drugs·2016
Same author

Biomarkers of Brain Structure and Function for Neurodegenerative Disorders: Are They Adequate for Go/No Go Decisions in Drug Development?

Clinical pharmacology and therapeutics·2015
Same author

Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy.

International journal of psychiatry in clinical practice·2014
Same author

Platelet α2-adrenoreceptors in depression: a critical examination.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Commentary on the management of treatment-resistant affective disorder: clinical perspectives.

Journal of psychopharmacology (Oxford, England)·2012
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Selective serotonin reuptake inhibitors are recommended as a first-line pharmacologic treatment for bipolar depression due to their safety and lower risk of inducing mania. Further research is needed for comprehensive treatment guidelines.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Bipolar depression is viewed as part of a spectrum of affective disorders.
  • Limited controlled data exist for treating the broader spectrum, with exceptions for Bipolar I disorder.

Purpose of the Study:

  • To review available pharmacologic treatments for bipolar depression.
  • To provide general recommendations for managing this condition.

Main Methods:

  • Review of existing clinical experience and small studies.
  • Analysis of available antidepressant and anticonvulsant medications.

Main Results:

  • Selective serotonin reuptake inhibitors (SSRIs) are considered the most comfortable first-line treatment.
  • SSRIs offer safety and a reduced likelihood of precipitating mania.

Related Experiment Videos

  • Other antidepressants and an anticonvulsant have demonstrated potential benefits in specific patient subgroups.

    • Conclusions:

    • While awaiting further controlled trials, SSRIs are a pragmatic choice for initial bipolar depression treatment.
    • The growing number of agents with diverse mechanisms offers potential advantages for patient subgroups.